Retatrutide for Type 2 Diabetes: TRANSCEND Trial Data

Overview

Type 2 diabetes is a central indication in retatrutide’s clinical development program. As a triple agonist of GIP, GLP-1, and glucagon receptors, retatrutide engages multiple pathways relevant to glycemic control: GLP-1 and GIP receptor activation stimulate glucose-dependent insulin secretion and suppress glucagon in the fed state, while the overall metabolic effects — including substantial weight loss and improved insulin sensitivity — address the underlying pathophysiology of type 2 diabetes.

In March 2026, Eli Lilly reported topline results from TRANSCEND-T2D-1, the first Phase 3 trial evaluating retatrutide specifically in adults with type 2 diabetes. These data confirm and extend the glycemic efficacy signals observed in the Phase 2 trial published by Rosenstock et al. in The Lancet (2023).

TRANSCEND-T2D-1: Phase 3 Results

Trial Design

TRANSCEND-T2D-1 was a randomized, double-blind, placebo-controlled Phase 3 trial evaluating retatrutide in adults with type 2 diabetes. Key parameters:

• Participants: 537
• Duration: 40 weeks
• Doses: 4 mg, 9 mg, and 12 mg (with dose escalation) vs. placebo
• Primary endpoint: Change in HbA1c from baseline
• Source: Eli Lilly press release, March 19, 2026. Full data are expected to be presented at the American Diabetes Association (ADA) Scientific Sessions in June 2026.

A1C Reduction

All active doses achieved statistically significant reductions in HbA1c versus placebo. The 9 mg dose produced the numerically largest reduction (-2.0%), with the 12 mg dose producing a similar result (-1.9%). The slightly lower A1C reduction at 12 mg compared to 9 mg may reflect a plateau in glycemic effect at higher doses, though both values are clinically meaningful and within the range of measurement variability.

Weight Loss

Weight loss in the type 2 diabetes population was substantial but lower than in the obesity population without diabetes (TRIUMPH-4 reported -28.7% at 12 mg over 68 weeks). This is consistent with a well-established pattern across incretin-based therapies: individuals with type 2 diabetes typically lose less weight than those without diabetes at equivalent doses. Contributing factors include differences in baseline metabolic status, concomitant diabetes medications, and the shorter trial duration (40 weeks vs. 68 weeks).

Notably, weight loss had not plateaued at 40 weeks, suggesting that longer treatment duration would yield additional weight reduction.

Safety and Tolerability

Gastrointestinal adverse events were the most common side effects, consistent with the GLP-1 class:

Dysesthesia was reported in 2.3-4.5% of retatrutide-treated participants in TRANSCEND-T2D-1. This is notably lower than the 8.8-20.9% observed in TRIUMPH-4’s obesity population. Whether this difference reflects the shorter duration, the diabetes population, or random variation is not yet clear.

Discontinuation due to adverse events was 2.2-5.1% across retatrutide doses, substantially lower than the 12.2-18.2% observed in TRIUMPH-4. This improved tolerability profile in the type 2 diabetes population is an important finding that may influence prescribing decisions and label language.

Key Takeaways from TRANSCEND-T2D-1

1. Retatrutide produced clinically meaningful A1C reductions across all doses, with the 9 mg dose achieving the largest numerical reduction (-2.0%).
2. Weight loss was substantial (-16.8% at 12 mg) and had not plateaued at 40 weeks.
3. The safety profile was more favorable than in the obesity population, with lower rates of dysesthesia and treatment discontinuation.
4. These are topline results from a press release; full data including subgroup analyses, secondary endpoints, and detailed safety data are expected at ADA June 2026.

Phase 2 Type 2 Diabetes Data

The Phase 2 trial in type 2 diabetes, published by Rosenstock et al. in The Lancet (2023), provided the initial evidence for retatrutide’s glycemic efficacy.

Study Design

• Participants: 281 adults with type 2 diabetes
• Duration: 36 weeks (with a 4-week follow-up)
• Doses: 0.5 mg, 4 mg (two regimens), 8 mg, 12 mg vs. dulaglutide 1.5 mg and placebo
• Population: Inadequately controlled type 2 diabetes (HbA1c 7.0-10.5%)

A1C Results at 36 Weeks

At the 12 mg dose, the A1C reduction of -2.02% at 36 weeks was the largest reported for a single agent in a Phase 2 diabetes trial. The Phase 3 TRANSCEND-T2D-1 results (-1.9% at 12 mg, 40 weeks) are consistent with this finding.

Cross-Trial Comparison with Other Therapies

Direct head-to-head comparisons between retatrutide and approved diabetes medications have not been completed, though the TRANSCEND-T2D-2 trial is designed as a head-to-head study against semaglutide. Until those data are available, only cross-trial comparisons are possible, with all the limitations that implies:

These comparisons should be interpreted with caution. Trial populations, baseline characteristics, concomitant medications, and endpoint definitions differ across programs. The TRANSCEND-T2D-2 head-to-head trial against semaglutide will provide the first direct comparison.

Retatrutide’s glycemic efficacy appears broadly comparable to tirzepatide, with numerically greater weight loss. Whether the triple agonist mechanism offers a clinically meaningful advantage over dual agonism for glycemic control specifically remains to be determined by direct comparison.

The TRANSCEND Clinical Program

The TRANSCEND program encompasses multiple Phase 3 trials evaluating retatrutide in type 2 diabetes and related conditions:

TRANSCEND-T2D-2 is of particular interest because it will provide the first head-to-head comparison of retatrutide against an established GLP-1 receptor agonist in a diabetes population. TRANSCEND-T2D-3 addresses a population with significant unmet need, as renal impairment limits therapeutic options and is a common complication of type 2 diabetes.

Mechanism of Action in Diabetes

Retatrutide’s triple receptor profile engages glycemic control through multiple complementary pathways:

• GLP-1 receptor agonism: Stimulates glucose-dependent insulin secretion, suppresses inappropriate glucagon release in the fed state, slows gastric emptying, and reduces appetite. This is the established mechanism shared with semaglutide, liraglutide, and other GLP-1 receptor agonists.
• GIP receptor agonism: Enhances the incretin effect, potentially improving beta-cell function and insulin sensitivity. This mechanism is shared with tirzepatide.
• Glucagon receptor agonism: Increases hepatic glucose output acutely, but in the context of sustained treatment with concurrent GLP-1/GIP agonism, the net metabolic effect is improved overall glycemic control. The glucagon component also drives increased energy expenditure, promoting the substantial weight loss that itself improves insulin sensitivity and glycemic control.

The combination of direct incretin-mediated insulin secretion, appetite-driven caloric reduction, and weight-loss-mediated improvements in insulin sensitivity likely accounts for the large A1C reductions observed across the clinical program.

Frequently Asked Questions

How does retatrutide compare to Mounjaro (tirzepatide) for diabetes?

No head-to-head data exist. In cross-trial comparisons, tirzepatide has produced slightly larger A1C reductions (up to -2.4% in the SURPASS program) while retatrutide produces greater weight loss (-16.8% vs. ~12.9% at comparable doses and durations). Both are developed by Eli Lilly. The TRANSCEND-T2D-2 trial comparing retatrutide to semaglutide will provide the first direct comparison against a GLP-1 agonist, but no tirzepatide head-to-head is currently planned.

Can retatrutide achieve diabetes remission?

The TRANSCEND-T2D-1 press release did not report diabetes remission rates (typically defined as A1C < 6.5% without medication). In the Phase 2 trial, 71% of participants at the 12 mg dose achieved A1C < 7.0%. Given the magnitude of A1C reduction and weight loss, some proportion of participants likely achieved remission-range A1C levels, but this will need to be confirmed in the full data presentation at ADA June 2026.

Why is the A1C reduction similar at 9 mg and 12 mg?

TRANSCEND-T2D-1 showed -2.0% at 9 mg and -1.9% at 12 mg. This may reflect a plateau in the dose-response curve for glycemic efficacy, where the incretin-mediated mechanisms are already maximally engaged at 9 mg. Weight loss, by contrast, continued to increase in a dose-dependent manner (-15.5% at 9 mg vs. -16.8% at 12 mg), suggesting that the higher dose provides additional metabolic benefit even if the direct glycemic effect has reached its ceiling.

When will retatrutide be approved for type 2 diabetes?

Retatrutide is not currently approved for any indication. Eli Lilly has stated that the TRANSCEND program data will support regulatory submissions, with the initial filing expected to focus on the TRIUMPH obesity program in late 2026. A separate diabetes indication filing would follow. The earliest approval for a type 2 diabetes indication would likely be 2028 or later, depending on regulatory timelines.

Why was weight loss lower in the diabetes population?

The -16.8% weight loss at 12 mg in TRANSCEND-T2D-1 (40 weeks) is lower than the -28.7% in TRIUMPH-4 (68 weeks). This difference reflects two factors: shorter treatment duration (40 vs. 68 weeks, with weight loss not yet plateaued) and the well-documented attenuation of weight loss in people with type 2 diabetes. Diabetes medications including insulin and sulfonylureas can promote weight gain, insulin resistance alters energy metabolism, and the metabolic environment in type 2 diabetes appears to resist weight loss relative to individuals without diabetes. This pattern is consistent across the GLP-1 agonist class.

What side effects were most common in the diabetes trial?

Gastrointestinal effects dominated: nausea (16.4-26.5%), diarrhea (18.7-26.3%), and vomiting (15.0-17.6%). Dysesthesia occurred in 2.3-4.5% of participants, lower than the 8.8-20.9% seen in the obesity population (TRIUMPH-4). Discontinuation due to adverse events was 2.2-5.1%, which is comparable to rates seen with other injectable incretins and substantially lower than TRIUMPH-4’s 12.2-18.2%. These data suggest that the tolerability profile may be more favorable in the type 2 diabetes population, though the shorter trial duration may also contribute.

Summary

The TRANSCEND-T2D-1 Phase 3 trial confirms retatrutide’s efficacy in type 2 diabetes, with A1C reductions of up to -2.0% and weight loss of -16.8% at 40 weeks. The safety profile was more favorable than in the obesity population, with lower dysesthesia rates and substantially lower treatment discontinuation. These data position retatrutide as a potentially significant addition to the type 2 diabetes therapeutic landscape, though direct comparisons with approved therapies await the TRANSCEND-T2D-2 head-to-head trial. Full TRANSCEND-T2D-1 data are expected at ADA June 2026.